Products

Pravastatin Sodium

HMG-CoA reductase is a rate-limiting enzyme in cholesterol biosynthesis. Pravastatin reversibly inhibits HMG-CoA reductase, causing subsequent reduction in cholesterol synthesis.

Mechanism of Action:

By reversibly inhibiting HMG-CoA reductase activity, the inhibitory mechanism of action produces a reduction in cholesterol biosynthesis which in order has been observed to increase the number of LDL receptors on cell surfaces and an enhancement in receptor-mediated metabolism of LDL and clearance.

On the other hand, pravastatin-driven inhibition of LDL production inhibits hepatic synthesis of VLDL as the LDL is the precursor for these molecules.

Therapeutic use

Pravastatin sodium is a lipid regulating drug and is an HMG-CoA reductase inhibitor.
Pravastatin Sodium

Chemical name

(+)-（ β R, δ R. 1S, 2S, 6S, 8S, 8aR) -1,2,6,7,8,8a - hexahydrogen- β,δ, 6,8-Tetrahydroxy-2-methyl-1-naphthylheptanoate sodium salt,8- [(2S) -2-methylbutyrate]

Product Parameters

Category

Active Pharmaceutical Ingredient (API)

Specifications

USP, EP, ChP, and JP

CAS No.

81131-70-6

Molecular formula

C23H35NaO7

Appearance

White to yellowish white powder or crystalline powder.

更多性能指标下载